Rockville, MD, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Based on a new research report published by Fact.MR, the global orally disintegrating tablet market is poised to reach a valuation of US$ 24.45 billion in 2024 and further advance at a CAGR of 11.5% from 2024 to 2034. Aftertaste and mouthfeel are two of the focus areas in which suppliers are active. More people are looking for tablets that are less bitter and work faster, which is where the market has the potential to evolve further over the coming years.
Orally disintegrating tablets (ODTs) have a pleasant mouthfeel, attracting a wide range of patients. These tablets do not require any additional liquid to swallow, making them suitable for use anywhere and at any time. The introduction of orally disintegrating tablets effectively addresses the challenge of swallowing traditional medications, particularly for babies, young children, and the elderly.
To improve their performance and desirability, ongoing developments in this field have resulted in the introduction of a variety of orally disintegrating pills with improved properties, such as better taste and faster disintegration. These advancements are key drivers for the increased adoption of orally disintegrating tablets, which are gaining prominence in the pharmaceutical industry.
For More Insights into the Market, Request a Sample of this Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=10142
Key Takeaways from Market Study:
- The global orally disintegrating tablet market is forecasted to reach a valuation of US$ 72.68 billion by the end of 2034.
- The market in North America is calculated to expand at a CAGR of 4% from 2024 to 2034.
- The United States is analyzed to hold a significant share of 5% in the North American region by the end of 2034.
- The market in Chile is projected to expand at a CAGR of 9% from 2024 to 2034.
- Based on drug class, demand for anxiolytics is calculated to increase at a CAGR of 5% from 2024 to 2034.
“ODTs offer ease of administration, promoting better patient adherence to treatment regimens compared to traditional tablets. Companies are focusing on improving the taste and mouthfeel of ODTs to ensure increased adoption among patients,” says a Fact.MR analyst.
Leading Players Driving Innovation in the Orally Disintegrating Tablets Market:
Johnson & Johnson Services Inc; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited; Eli Lily and Company; Dr. Reddy’s Laboratories Ltd; Mylan N.V.; Bausch Health; GlaxoSmithKline Plc; Merck & Co Inc.; AstraZeneca; Bayer AG; F Hoffman-La Roche Ltd.
High Level of Patient Compliance with ODTs:
Orally disintegrating tablets have established a niche among oral drug delivery systems due to the high level of compliance they achieve in patients, particularly in geriatrics and pediatrics. Patients with dysphagia, motion sickness, repeated emesis, and mental disorders prefer these medications because they are unable to swallow large amounts of water.
Drugs with good oral mucosal absorption or with immediate pharmacological action can be formulated in these dosage forms. However, the need to formulate these dosage forms with mechanical strength sufficient to withstand the rigors of handling while also disintegrating within a few seconds in contact with saliva is inextricably linked.
Orally Disintegrating Tablets Industry News:
Orally disintegrating tablets (ODTs) are a very competitive business, with a number of well-established and up-and-coming companies fighting for share.
Research, development, and commercialization of ODTs and other pharmaceutical products are undertaken by companies.
Among the primary tactics employed by these companies to hold onto and increase their market share are product innovation, joint ventures and alliances, mergers and acquisitions, and regional growth. Oral antivirals and oral solid dosage contracts are two emerging industry trends that major competitors in the oral disintegrating tablet market are adjusting to.
Get Customization on this Report for Specific Research Solutions-https://www.factmr.com/connectus/sample?flag=S&rep_id=10142
More Valuable Insights on Offer:
Fact.MR, in its new offering, presents an unbiased analysis of the orally disintegrating tablet market for 2019 to 2023 and forecast statistics for 2024 to 2034.
The study divulges essential insights into the market based on drug class (anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-parkinsonian drugs, anti-hypertensives, NSAIDs, anti-allergy drugs, proton pump inhibitors, others), disease indication (CNS diseases, GI diseases, CVS disorders, allergies, others), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).
Checkout More Related Studies Published by Fact.MR Research:
The global achalasia treatment market is currently valued at around US$ 472.12 million in 2024 and is forecasted to expand at a CAGR of 9.1% to reach US$ 1.13 billion by the end of 2034.
The global artificial eyes market is approximated to reach a valuation of US$ 2.3 billion in 2024 and further expand at a CAGR of 8.7% to end up at US$ 5.27 billion by the year 2034.
The global electromagnetic navigation bronchoscopy market is evaluated to reach a value of US$ 124.35 million in 2024 and is forecasted to expand at a CAGR of 8.9% to reach US$ 292.77 million by 2034.
The global endoscopic balloon dilator market is projected to generate revenue worth US$ 804.52 million in 2024 and has been thoroughly analyzed to increase at a CAGR of 9.2% to achieve a value of US$ 1.94 billion by 2034-end.
The global wax removal aid market is estimated at US$ 220.08 million in 2024. The market has been forecasted to increase at a CAGR of 5.8% and touch a value of US$ 386.32 million by the end of 2034.
About Us:
Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning. With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog
